Premier Asset Management LLC reduced its position in Pfizer, Inc. (NYSE:PFE) by 6.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 37,146 shares of the biopharmaceutical company’s stock after selling 2,550 shares during the period. Premier Asset Management LLC’s holdings in Pfizer were worth $1,247,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Shine Investment Advisory Services Inc. bought a new stake in shares of Pfizer in the 2nd quarter valued at about $102,000. D. Scott Neal Inc. boosted its holdings in shares of Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC bought a new stake in shares of Pfizer in the 1st quarter valued at about $121,000. Cascade Investment Advisors Inc. boosted its holdings in shares of Pfizer by 89.1% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,200 shares in the last quarter. Finally, Perennial Advisors LLC boosted its holdings in shares of Pfizer by 7.9% in the 2nd quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 376 shares in the last quarter. Institutional investors and hedge funds own 69.36% of the company’s stock.

Pfizer, Inc. (PFE) opened at $35.56 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The firm has a market cap of $210,770.61, a P/E ratio of 14.14, a PEG ratio of 2.50 and a beta of 1.01. Pfizer, Inc. has a 1-year low of $30.51 and a 1-year high of $36.78.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.61 EPS. sell-side analysts anticipate that Pfizer, Inc. will post 2.6 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.60%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is 79.01%.

PFE has been the subject of several research analyst reports. BMO Capital Markets reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Pfizer in a research report on Wednesday, September 6th. UBS AG reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a research report on Monday, July 31st. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, August 14th. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, September 19th. Finally, Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Tuesday, October 3rd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. Pfizer currently has a consensus rating of “Hold” and an average target price of $38.48.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/pfizer-inc-pfe-stake-decreased-by-premier-asset-management-llc/1708550.html.

In related news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction on Monday, August 21st. The shares were sold at an average price of $32.70, for a total value of $263,692.80. Following the sale, the insider now owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total transaction of $262,027.50. Following the completion of the sale, the executive vice president now directly owns 117,432 shares in the company, valued at approximately $4,186,450.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 374,621 shares of company stock valued at $12,796,098. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.